Journal Of Clinical Oncology (jco) Podcast

Amongst several different liver directed therapy approaches, chemoembolization (called TACE) and radiofrequency ablation (called RFA) are most commonly used worldwide. However, the efficacy of TACE and RFA remains limited.

A discussion of a phase 2 trial of a MEK inhibitor in patients with V600 BRAF mutations and consideration of other relevant results with targeted therapies in this population.

This podcast discusses therapeutic options for MDS patients including azacytidine and allogeneic stem cell transplantation.

This video support tool describing CPR lets patients make much better informed decisions about the use of CPR. Physicians often feel that CPR will not be of help to patients but nevertheless feel obligated to offer it or not withhold it. This video support tool describing CPR might enable patients to make much better informed decisions about the use of CPR. Letting patients view this 6 minute video convinced the great majority of them that CPR would not be unlikely to help them, which is very consistent with the medical facts. Nearly all of them felt very comfortable with watching the video. Maybe we should have this in a looptool available in every oncologist’s office.

Radioimmunotherapy alone or in sequential combination with chemotherapy is effective initial treatment for follicular lymphoma, though comparable (and not superior) to other management options for this population.

Whole-brain radiation therapy of metastases to the brain is not innocuous - it is associated with decrements in health-related quality of life. It is still unknown if the potential benefits outweigh the impact of the side effects.

This is a commentary on the role of MET in cancer using Choueri et al as an example of rationale therapeutics and translational research.

A discussion of treatment approaches for newly diagnosed aggressive AIDS-related lymphomas

Seven year follow up of B-31 demonstrates a striking and reassuring lack of longer-term cardiac events.

More adjuvant chemotherapy is not always better for early breast cancer patients - Discussion and consequence for clinical practice.

The podcast reviews the evolution of staging and treatment of Hodgkin lymphoma, reducing the toxicities and torture while maintaining a high level of cure.

In this podcast, Attar and colleagues explore whether patients aged 60-75 who enter remission with bortezomib added to standard anthracycline plus cytarabine chemotherapy during induction can be safely treated with intermediate dose cytarabine along with dose escalating bortezomib during consolidation. This regimen was tolerated at the highest dose of bortezomib tested, 1.3 mg/m2, and further randomized studies of this regimen will be planned.

This podcast will review a JCO article showing that the use of breast brachytherapy as a method of delivering partial breast radiation after breast conserving surgery was associated with higher rates of complications than the conventional approach of whole breast radiation.

This Podcast provides observations and commentary about referral practices of oncologists to specialized palliative care.

This podcast characterizes the clinical utility of the screening tests recommended by the Children’s Oncology Group in the care of long-term survivors.

Publication of a large collaborative group trial appears to definitively demonstrate the safety of sentinel lymph node biopsy as replacement for inguinal-femoral lymphadenectomy, or does it?

In this podcast, results of a randomized phase III clinical trial evaluating the use of Rituximab maintenance therapy following autologous stem cell transplantation in patients with relapsed diffuse large B cell lymphoma are summarized. The results demonstrate that Rituximab maintenance therapy does not result in improved event free or overall survival in this patient population.

Melissa Cousino and colleagues found that few parents understand the scientific purpose of phase I pediatric clinical trials.

The prognostic importance of ALK-protein expression was established over a decade ago. More recent studies emphasize that age is also an important driving force and in patients

Although gemtuzumab ozogamicin has been withdrawn from the marketplace, three randomized trials prompt review of that decision.